Revelation Biosciences, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-05-20. It has amended it 1 time. As of its latest filing, on 2025-05-23, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock and warrants sold in our initial public offering (“Public Warrants”) are listed on The Nasdaq Stock Market, LLC (“Nasdaq”) under the ticker symbol “REVB” and “REVBW,” respectively.From the S-1/A filed 2025-05-23
Use of proceeds
We currently intend to use the net proceeds we receive from this offering to further the development of our Product Candidates including the (i) the completion of our ongoing Phase 1b clinical study, (ii) the manufacture of clinical drug supply, (iii) additional preclinical work for multiple indications, (iv) continue to develop other products and therapies, and (v) fund working capital and general corporate purposes using any remaining amounts.From the S-1/A filed 2025-05-23
Net loss or income
We have incurred recurring losses since our inception, including a net loss of $15.0 million for the year ended December 31, 2024 and $0.1 million for the year ended December 31, 2023, respectively and a net of loss $2.1 million for the three months ended March 31, 2025 and $2.7 million for the three months ended March 31, 2024, respectively.From the S-1/A filed 2025-05-23
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-05-20 | Registration statement filed | S-1 |
| 2025-05-23 | Registration statement amended | S-1/A |
Tools for this story
Each opens in a new tab, filled in for Revelation Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.